ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2829

Adherence to Treatment and Renal Transplantation Graft Failure in Lupus Nephritis

Eleana Ntatsaki1, Alba Velo Garcia2, Alan D. Salama3 and David A. Isenberg4, 1Centre for Rheumatology, University College London, London, United Kingdom, 2Internal Medicine Department, University Hospital Complex of Pontevedra, Pontevedra, Spain, 3Centre for Nephrology, University College London, London, United Kingdom, 4Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Compliance, Lupus nephritis, outcomes, transplantation and treatment

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster III: Biomarkers and Nephritis

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Patient non-adherence has been reported as a potential adverse outcome predictor in renal transplantation (rTp) for patients with lupus nephritis (LN). We investigated potential factors leading to non-adherence and whether non-adherence is associated with increased rTp graft failure.

Methods: Patients with LN undergoing rTp in two major institutions were retrospectively included in this study, analysing prospectively captured data. The medical notes were reviewed for any documented concerns about non-adherence to prescribed treatment. Laboratory biochemical results (tacrolimus, mycophenalate mofetil (MMF) and ciclospirin levels) were also reviewed for evidence of non-adherence, defined as evidence of sub- therapeutic drug levels in routine measuring in >25% occurrences. Potential associations with poor adherence were examined including age, sex, race, age at SLE diagnosis, age at lupus nephritis diagnosis, age when dialysis was started, duration of SLE diagnosis, duration of lupus nephritis diagnosis, time on dialysis prior to rTp and medication use.

Results: All patients with rTp since 1975 were included. Forty patients had rTp from a total of 361 lupus patients in both centres. For 10 patients there were concerns documented in the medical records for non-adherence. For 9 patients (out of 16 biochemically tested) there was evidence of non-adherence, giving a total of 16 unique patients with concern about possible non-adherence to prescribed treatment for LN. There were no associations between patient demographics and non-adherence. In particular, in this cohort there was no association between age at SLE diagnosis or rTp, gender, race and diagnosis duration or medication prescribed and non-adherence (Table 1). However, having recorded a concern about possible non-adherence showed a trend in associating with increased graft rejection, hazard ratio of 3.40 when concerns existed compared to when no concerns were raised (95% CI=0.732-15.723, p=0.118).

Conclusion: There were no significant factors associating with non-adherence in this cohort. However, a concern about possible non-adherence (either recorded in the notes or as evidenced with biochemical assays) showed a trend towards a 3.4 higher risk of graft rejection. Further larger studies are warranted to investigate further the factors leading to non-adherence, and the true adverse effect of non-adherence on rTp in the context of LN.

Non-adherent

Adherent

Gender (men/ women)

3/ 13

3/ 21

Ethnicity

Caucasian

6

9

Afro-Caribbean

5

10

Asian

5

5

Age at SLE diagnosis (years)

20 ±11

22±9

Age at LN diagnosis (years)

26±6

27±8

Age at ESRF (years)

32±12

31±10

Age at rTp (years)

34±11

37±11

Graft failure

6

4

Table 1 Patient demographic and characteristics in patients with non-adherence concerns versus patients where no concerns about non-adherence were raised.


Disclosure: E. Ntatsaki, None; A. Velo Garcia, None; A. D. Salama, None; D. A. Isenberg, None.

To cite this abstract in AMA style:

Ntatsaki E, Velo Garcia A, Salama AD, Isenberg DA. Adherence to Treatment and Renal Transplantation Graft Failure in Lupus Nephritis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/adherence-to-treatment-and-renal-transplantation-graft-failure-in-lupus-nephritis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/adherence-to-treatment-and-renal-transplantation-graft-failure-in-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology